Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease

  title={Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease},
  author={E. Heinonen and V. Myllyl{\"a}},
  journal={Drug Safety},
  • E. Heinonen, V. Myllylä
  • Published 1998
  • Medicine
  • Drug Safety
  • Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson’s disease. As the first MAO-B inhibitor approved for the treatment of Parkinson’s disease, concerns were raised about the safety of the drug based on the adverse effect profiles of older, nonselective MAO inhibitors. Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the ‘cheese effect’) at… CONTINUE READING
    72 Citations
    Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease
    • 11
    Selegiline: A Reappraisal of Its Role in Parkinson Disease
    • 31
    • Highly Influenced
    Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
    • B. Robottom
    • Medicine
    • Patient preference and adherence
    • 2011
    • 27
    • PDF
    Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease
    • 53
    • PDF
    MAO-inhibitors in Parkinson's Disease
    • 140
    • PDF
    Monamine Oxidase Inhibitors: Current and Emerging Agents for Parkinson Disease
    • 60
    Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease
    • 261
    Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease
    • M. Lew
    • Medicine
    • Expert review of neurotherapeutics
    • 2005
    • 17
    Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease
    • PDF


    Role of selegiline in combination therapy of Parkinson's disease
    • 22
    The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    • 594
    • Highly Influential
    Psychiatric effects of selegiline.
    • 14
    Selegiline in Parkinson's disease
    • 37
    Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    • 53
    Fluoxetine and selegiline--lack of significant interaction.
    • C. Waters
    • Medicine
    • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
    • 1994
    • 38
    • PDF
    Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease
    • 177
    Selegiline in the early and late phases of Parkinson's disease.
    • 28